TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2693431

Group type: EXPERIMENTAL
Intervention: Individualized pharmacokinetic (PK) dosing of amikacin
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard (every 12 h) dosing of amikacin
Number of subjects: 82
Study: 681132

Group type: EXPERIMENTAL
Intervention: 50 mg thioridazine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30785496

Group type: EXPERIMENTAL
Intervention: Oregano essential oil (OEO) at 150 mg.kg‐1
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Oregano essential oil (OEO) at 200 mg.kg‐1
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control treatment (CT) with zinc bacitracin
Number of subjects: 240
Study: 29392288

Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 mg)
Number of subjects: 546
Study: 25731901

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 200 mg
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 400 mg
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 200 mg (2 doses)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 400 mg (2 doses)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Reference group (no NAC)
Number of subjects: 171
Study: 24327455

Group type: EXPERIMENTAL
Intervention: Pedicled 'no-touch' (NT) technique
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional (CON) technique
Number of subjects: 17
Study: 22950861

Group type: EXPERIMENTAL
Intervention: Topiramate (10 mg/kg once a day for the first 3 days of life) with moderate hypothermia
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard treatment with moderate hypothermia alone
Number of subjects: 64
Study: 21058473

Group type: EXPERIMENTAL
Intervention: G‐CSF plus acupuncture (A)
Number of subjects: 86

Group type: COMPARATOR
Intervention: G‐CSF
Number of subjects: 86
Study: 17558118

Group type: EXPERIMENTAL
Intervention: Perindopril +/‐ indapamide
Number of subjects: 298
Study: 16306522

Group type: EXPERIMENTAL
Intervention: Timolol (nonselective beta-blocker)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 11989511

Group type: EXPERIMENTAL
Intervention: Low-volume exercise rehabilitation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Normal activity
Number of subjects: 2
Study: 10096387

Group type: EXPERIMENTAL
Intervention: Finasteride treatment for 24 to 30 months
Number of subjects: 19
Study: 7674643

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2291868

Group type: EXPERIMENTAL
Intervention: Captopril (12.5, 25 and 50 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oxazepam (15 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Atenolol (100 mg)
Number of subjects: 14
Study: 7316551

Group type: EXPERIMENTAL
Intervention: Topical exothermic pads (hyperthermia)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Goeckerman's regimen (control)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hyperthermia and Goeckerman's regimen (combined)
Number of subjects: 22
Study: 31112385

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benralizumab 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benralizumab 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg (TERRANOVA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benralizumab 100 mg (TERRANOVA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (TERRANOVA)
Number of subjects: 0
Study: 28875371

Group type: EXPERIMENTAL
Intervention: Heparin group (heparin bolus 70 IU per kg body weight before PA catheter insertion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (pretreatment with placebo)
Number of subjects: 60
Study: 26527466

Group type: EXPERIMENTAL
Intervention: Water exercise + BFR
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Water exercise only
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 24447181

Group type: EXPERIMENTAL
Intervention: Resting echocardiographic optimization of CRT (AV delay plus VV delay)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Resting echocardiographic optimization
Number of subjects: 59

Group type: COMPARATOR
Intervention: Exercise echocardiographic optimization
Number of subjects: 59

Group type: COMPARATOR
Intervention: No optimization
Number of subjects: 59
Study: 21573917

Group type: EXPERIMENTAL
Intervention: Bursectomy
Number of subjects: 210

Group type: COMPARATOR
Intervention: Non-bursectomy
Number of subjects: 210
Study: 19909743

Group type: EXPERIMENTAL
Intervention: 5% mannitol meal (350 mL)
Number of subjects: 54

Group type: COMPARATOR
Intervention: 5% glucose meal (350 mL)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 331-kcal meal with bran
Number of subjects: 54

Group type: COMPARATOR
Intervention: 331-kcal meal without bran
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: IBS-D diet with bran meal
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: IBS-D patients
Number of subjects: 54
Study: 17505641

Group type: EXPERIMENTAL
Intervention: Myocardial revascularization procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggressive control of glycemic levels, strict management of all conventional risk factors, and lifestyle modification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin sensitizers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New therapeutic modalities
Number of subjects: 0
Study: 15636619

Group type: EXPERIMENTAL
Intervention: Preemptive standard (IFN) or pegylated (peg-IFN) interferon alfa-2b (3 MU thrice weekly or 1.5 microg/kg weekly) plus ribavirin (600 mg increased to 1.0-1.2 g daily) initiated 2-6 weeks post-transplantation for 48 weeks
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Combination therapy (IFN/peg-IFN plus ribavirin)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Growth factor (GF) use (erythropoietin and GCSF)
Number of subjects: 124
Study: 12132563

Group type: EXPERIMENTAL
Intervention: Oral gemifloxacin
Number of subjects: 438

Group type: COMPARATOR
Intervention: Oral clarithromycin
Number of subjects: 438
Study: 10212514

Group type: EXPERIMENTAL
Intervention: Artesunate (700 mg oral for 5 days)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Quinine + tetracycline (7-day regimen)
Number of subjects: 137
Study: 7790130

Group type: EXPERIMENTAL
Intervention: Perceived risk of infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV knowledge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived susceptibility to HIV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived peer norms regarding drug-related risk reduction
Number of subjects: 0
Study: 2127095

Group type: EXPERIMENTAL
Intervention: Cooperative Care (CC) program
Number of subjects: 0
Study: 7005645

Group type: EXPERIMENTAL
Intervention: Intensive treatment (cyclophosphamide 200 mg/m2 IV weekly x 4 and Adriamycin 40 mg/m2 IV weeks 1 and 3)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No intensive treatment (control group)
Number of subjects: 54
Study: 31112442

Group type: EXPERIMENTAL
Intervention: In-clinic CBT for anxiety
Number of subjects: 50

Group type: COMPARATOR
Intervention: iGlebe (5 months online access)
Number of subjects: 50
Study: 28219383

Group type: EXPERIMENTAL
Intervention: Tailored, multidimensional transitional care package
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 25733246

Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23858729

Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroids
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Leukotriene receptor antagonists
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 21889250

Group type: COMPARATOR
Intervention: Dynamic control condition (focus on dynamic features of the task)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spatial control condition (focus on visuomotor features of the task)
Number of subjects: 0
Study: 19132857

Group type: EXPERIMENTAL
Intervention: CSII with RT-CGM as an adjunct to SMBG (n = 14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Multiple daily injections (MDI) and self-monitoring of blood glucose (SMBG) (control arm)
Number of subjects: 28
Study: 17262200

Group type: EXPERIMENTAL
Intervention: Crohn's disease
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Ulcerative colitis
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Ocular involvement
Number of subjects: 116
Study: 16508637

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI (CPT‐11 150 mg m(‐2) on d1, L‐OHP 65 mg m(‐2) on d2, LV 200 mg m(‐2) on days 2 and 3, 5‐FU 400 mg m(‐2) as i.v. bolus and 600 mg m(‐2) as 22 h i.v. continuous infusion on days 2 and 3, every 2 weeks)
Number of subjects: 283

Group type: COMPARATOR
Intervention: FOLFIRI (CPT‐11 180 mg m(‐2) on d1, LV and 5‐FU administered as in FOLFOXIRI, every 2 weeks)
Number of subjects: 283
Study: 12773077

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: eptifibatide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tirofiban
Number of subjects: 0
Study: 11095480

Group type: EXPERIMENTAL
Intervention: CNC patients (18 women)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (11 women)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Registry of 178 CNC patients
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CNC patients (12 who died of other causes)
Number of subjects: 18
Study: 9001874

Group type: EXPERIMENTAL
Intervention: Double gloving with an inner coloured pair of gloves
Number of subjects: 100

Group type: COMPARATOR
Intervention: Double gloving with classic gloves
Number of subjects: 100
Study: 1473453

Group type: EXPERIMENTAL
Intervention: Carteolol 2%
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Carteolol 2% with FAT-MLV
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (FAT-MLV)
Number of subjects: 75
Study: 6364396

Group type: EXPERIMENTAL
Intervention: Full-strength cow's milk (FCM)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Graduated milk
Number of subjects: 74
Study: 31231838

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg/day
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (not diagnosed with ED)
Number of subjects: 143
Study: 28634217

Group type: EXPERIMENTAL
Intervention: Participants with SBP/DBP <140/90 mm Hg
Number of subjects: 31856

Group type: EXPERIMENTAL
Intervention: Participants taking antihypertensive medication with SBP/DBP <140/90 mm Hg
Number of subjects: 31856

Group type: EXPERIMENTAL
Intervention: Participants not taking antihypertensive medication with SBP/DBP <140/90 mm Hg
Number of subjects: 31856

Group type: EXPERIMENTAL
Intervention: Participants <65 years of age with SBP/DBP <140/90 mm Hg
Number of subjects: 31856

Group type: EXPERIMENTAL
Intervention: Participants =65 years of age with SBP/DBP <140/90 mm Hg
Number of subjects: 31856

Group type: EXPERIMENTAL
Intervention: Women with SBP/DBP <140/90 mm Hg
Number of subjects: 31856

Group type: EXPERIMENTAL
Intervention: Men with SBP/DBP <140/90 mm Hg
Number of subjects: 31856

Group type: EXPERIMENTAL
Intervention: Whites with SBP/DBP <140/90 mm Hg
Number of subjects: 31856

Group type: EXPERIMENTAL
Intervention: Blacks with SBP/DBP <140/90 mm Hg
Number of subjects: 31856

Group type: EXPERIMENTAL
Intervention: Hispanics with SBP/DBP <140/90 mm Hg
Number of subjects: 31856

Group type: EXPERIMENTAL
Intervention: Chinese-Americans with SBP/DBP <140/90 mm Hg
Number of subjects: 31856
Study: 26210342

Group type: EXPERIMENTAL
Intervention: Usual care plus supplemental education intervention
Number of subjects: 711

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 711
Study: 23937346

Group type: EXPERIMENTAL
Intervention: Web-based Personalized Normative Feedback (PNF) using typical student norms
Number of subjects: 1663

Group type: EXPERIMENTAL
Intervention: Web-based Personalized Normative Feedback (PNF) using specific reference groups
Number of subjects: 1663

Group type: COMPARATOR
Intervention: Repeated-assessment control
Number of subjects: 1663

Group type: COMPARATOR
Intervention: Web-BASICS intervention
Number of subjects: 1663
Study: 21350366

Group type: COMPARATOR
Intervention: Engerix B, 20 μg HBsAg
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Engerix B, 40 μg
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Twinrix, 20 μg HBsAg combined with 720 ELU hepatitis A antigen
Number of subjects: 336
Study: 18637980

Group type: COMPARATOR
Intervention: Women without hypertension
Number of subjects: 7149

Group type: EXPERIMENTAL
Intervention: Women with hypertension
Number of subjects: 7149
Study: 17306408

Group type: EXPERIMENTAL
Intervention: Rehabilitation interventions based on the SOFMER methodology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparative controlled studies including randomized controlled trials, controlled clinical trials, cohort studies, case control studies, reviews of clinical trials, and case series
Number of subjects: 0
Study: 15569067

Group type: EXPERIMENTAL
Intervention: Whole blood stored for 1, 2, 6, or 18 hours before filtration
Number of subjects: 48
Study: 11360130

Group type: EXPERIMENTAL
Intervention: Child-targeted nutrition counselling
Number of subjects: 140
Study: 9765723

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus supportive care
Number of subjects: 1190

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens containing cisplatin
Number of subjects: 1190

Group type: COMPARATOR
Intervention: Chemotherapy (not specified)
Number of subjects: 1190

Group type: COMPARATOR
Intervention: Chemotherapy using long-term alkylating agents other than cisplatin
Number of subjects: 1190

Group type: COMPARATOR
Intervention: Chemotherapy (general)
Number of subjects: 1190

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 1190
Study: 8119822

Group type: EXPERIMENTAL
Intervention: Leukocyte filtration using a leukocyte filter incorporated in the bypass circuit (n = 8)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 15
Study: 3691624

Group type: EXPERIMENTAL
Intervention: Amodiaquine 200 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Amodiaquine 400 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Amodiaquine 600 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Amodiaquine 200 mg, 400 mg, 600 mg
Number of subjects: 6
Study: 29273892

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 49
Study: 27033753

Group type: EXPERIMENTAL
Intervention: HHT
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: DNR
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: HHT + DNR
Number of subjects: 96
Study: 25623162

Group type: EXPERIMENTAL
Intervention: Computerised intervention in addition to usual care
Number of subjects: 285

Group type: COMPARATOR
Intervention: Attention and activity control in addition to usual care
Number of subjects: 285

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 285
Study: 23664208

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of ranibizumab and PDT
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cataract surgery (Control)
Number of subjects: 20
Study: 21920206

Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous electrical nerve stimulation) for one hour
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (G2) without TENS (electrodes placed but equipment not turned on)
Number of subjects: 30
Study: 18158000

Group type: EXPERIMENTAL
Intervention: Training and Support Program (TSP); 8 weekly sessions, 1 hour each, taught by qualified therapists.
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group (wait-list); offered TSP after 4 months.
Number of subjects: 188
Study: 16259645

Group type: EXPERIMENTAL
Intervention: 30 mg/d nemifitide
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 45 mg/d nemifitide
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 12611031

Group type: EXPERIMENTAL
Intervention: Social skills training (SST) for 8 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: No-intervention control condition
Number of subjects: 120
Study: 10674778

Group type: EXPERIMENTAL
Intervention: Respiratory syncytial virus immune globulin intravenous (RSV‐IGIV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RSV‐IGIV or palivizumab
Number of subjects: 0
Study: 8831163

Group type: EXPERIMENTAL
Intervention: Imaginary trauma writing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real trauma writing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both trauma groups (Imaginary and Real)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (trivial events)
Number of subjects: 0
Study: 1280735

Group type: EXPERIMENTAL
Intervention: SCH 34826 (400 mg every 6 hours for five doses)
Number of subjects: 6
Study: 3966709

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31334680

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted suprapubic salpingectomy (LASS)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional laparoscopy (CL)
Number of subjects: 57
Study: 30366815

Group type: EXPERIMENTAL
Intervention: Pegvaliase (recombinant Anabaena variabilis phenylalanine ammonia lyase conjugated with polyethylene glycol)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Pegvaliase
Number of subjects: 261
Study: 27132170

Group type: EXPERIMENTAL
Intervention: Myrcludex B
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PegIFNα‐2a
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Myrcludex B + PegIFNα‐2a
Number of subjects: 24
Study: 26016365

Group type: EXPERIMENTAL
Intervention: Heat acclimation training (including meditation, unarmed run, yoga, and stepping in hot lab environment)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Heat acclimation training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 40
Study: 23259260

Group type: EXPERIMENTAL
Intervention: Paraplegia-triple-needling method combined with conventional rehabilitation training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional acupuncture therapy combined with conventional rehabilitation training
Number of subjects: 48
Study: 21082868

Group type: EXPERIMENTAL
Intervention: Anacetrapib 100 mg daily for 18 months
Number of subjects: 1623

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1623
Study: 17573687

Group type: EXPERIMENTAL
Intervention: Bayesian perspective in clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian philosophy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suggestions for Bayesians
Number of subjects: 0
Study: 16190570

Group type: EXPERIMENTAL
Intervention: Pegylated interferon-based retherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pegylated interferon and ribavirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with pegylated interferon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily administration of consensus interferon and ribavirin
Number of subjects: 0
Study: 12521969

Group type: EXPERIMENTAL
Intervention: Single education session for nursing staff and provision of three hip protectors per resident
Number of subjects: 942

Group type: COMPARATOR
Intervention: Usual care with brief information to nursing staff and provision of two hip protectors per cluster
Number of subjects: 942
Study: 11431944

Group type: EXPERIMENTAL
Intervention: 50 mg/kg tranexamic acid before skin incision and after the start of cardiopulmonary bypass
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no tranexamic acid)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 50 mg/kg tranexamic acid
Number of subjects: 14
Study: 9191679

Group type: EXPERIMENTAL
Intervention: Unreamed femoral nailing
Number of subjects: 39

Group type: COMPARATOR
Intervention: Reamed femoral nailing
Number of subjects: 39
Study: 1447560

Group type: EXPERIMENTAL
Intervention: Normal reading speed (first paragraph)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Filled text condition (second paragraph)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Randomized spaces condition (third paragraph)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (normal paragraph)
Number of subjects: 45
Study: 3722838

Group type: EXPERIMENTAL
Intervention: Long-term indwelling catheters
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bed-pads
Number of subjects: 16
Study: 28673805

Group type: EXPERIMENTAL
Intervention: Polyvinyl Alcohol (PVA) gelatin tubes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Silicone tubes
Number of subjects: 0
Study: 27334236

Group type: EXPERIMENTAL
Intervention: Low-energy diet (LED) for 16 weeks (8 weeks LED + 8 weeks normal food intake with 2 LED products/day) followed by 48 weeks of weight maintenance diet
Number of subjects: 60
Study: 24756913

Group type: EXPERIMENTAL
Intervention: Routine duplex ultrasonography
Number of subjects: 94

Group type: COMPARATOR
Intervention: Selective duplex ultrasonography
Number of subjects: 94
Study: 22840421

Group type: EXPERIMENTAL
Intervention: Lutein plus zeaxanthin (L+Z) 10 mg/2 mg; n = 1044
Number of subjects: 4203

Group type: EXPERIMENTAL
Intervention: ω‐3 long‐chain polyunsaturated fatty acids (LCPUFA) (eicosapentaenoic acid + docosahexaenoic acid [650 mg/350 mg]; n = 1069)
Number of subjects: 4203

Group type: EXPERIMENTAL
Intervention: Combination of L+Z and ω‐3 LCPUFAs; n = 1078
Number of subjects: 4203

Group type: EXPERIMENTAL
Intervention: Original AREDS formulation with variations in zinc and β‐carotene
Number of subjects: 4203

Group type: COMPARATOR
Intervention: Placebo; n = 1012
Number of subjects: 4203